$17.58
3.96% yesterday
Nasdaq, Nov 25, 10:00 pm CET
ISIN
IL0011280240
Symbol
ARCT
Sector
Industry

Arcturus Therapeutics Ltd Stock price

$17.58
-1.37 7.23% 1M
-12.83 42.19% 6M
-13.95 44.24% YTD
-8.22 31.86% 1Y
-18.43 51.18% 3Y
+7.63 76.68% 5Y
-6.64 27.42% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
+0.67 3.96%
ISIN
IL0011280240
Symbol
ARCT
Sector
Industry

Key metrics

Market capitalization $476.20m
Enterprise Value $213.44m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 1.47
P/S ratio (TTM) P/S ratio 3.27
P/B ratio (TTM) P/B ratio 1.82
Revenue growth (TTM) Revenue growth -50.30%
Revenue (TTM) Revenue $145.60m
EBIT (operating result TTM) EBIT $-30.45m
Free Cash Flow (TTM) Free Cash Flow $-61.26m
Cash position $292.18m
EPS (TTM) EPS $-2.21
P/E forward negative
P/S forward 2.75
EV/Sales forward 1.23
Short interest 26.51%
Show more

Is Arcturus Therapeutics Ltd a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Arcturus Therapeutics Ltd Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Arcturus Therapeutics Ltd forecast:

11x Buy
100%

Analyst Opinions

11 Analysts have issued a Arcturus Therapeutics Ltd forecast:

Buy
100%

Financial data from Arcturus Therapeutics Ltd

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
146 146
50% 50%
100%
- Direct Costs 3.52 3.52
-
2%
142 142
-
98%
- Selling and Administrative Expenses 46 46
2% 2%
32%
- Research and Development Expense 123 123
9% 9%
85%
-27 -27
121% 121%
-18%
- Depreciation and Amortization 3.52 3.52
34% 34%
2%
EBIT (Operating Income) EBIT -30 -30
124% 124%
-21%
Net Profit -60 -60
160% 160%
-41%

In millions USD.

Don't miss a Thing! We will send you all news about Arcturus Therapeutics Ltd directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Arcturus Therapeutics Ltd Stock News

Neutral
Business Wire
7 days ago
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that the Company will present at Jefferies London Healthcare Conference in London, o...
Negative
Seeking Alpha
12 days ago
Interim results from phase 2 proof-of-concept study, using LUNAR-CF for treatment of patients with Cystic Fibrosis, expected 1st half of 2025. The global Cystic Fibrosis market size is projected to reach $62.57 billion by 2032. Interim results from phase 2 proof-of-concept study, using LUNAR-OTC for treatment of patients with OTC Deficiency, expected 1st half of 2025.
Neutral
Business Wire
12 days ago
TOKYO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan, President and Representative Director: Daikichiro Kobayashi; hereinafter referred to as "Meiji Seika Pharma") today announced its investment in ARCALIS, Inc. (Headquarters: Minami-soma City, Fukushima Prefecture; President: Satoshi Takamatsu; hereinafter referred to as "ARCALIS"). ARCALIS ...
More Arcturus Therapeutics Ltd News

Company Profile

Arcturus Therapeutics Holdings, Inc. engages in the research and development of medical applications for the nucleic acid-focused technology. The firm develops RNA therapeutics which focuses on the treatment of liver and respiratory diseases. Its pipeline include LUNAR-OTC and LUNAR CF. The company was founded in 2013 and is headquartered in San Diego, CA.

Head office Israel
CEO Joseph Payne
Employees 180
Founded 2013
Website www.arcturusrx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today